Please assess the completion status of the following clinical trial:

Trial Title: Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histological confirmation of primary myelofibrosis or post essential thrombocythemic or polycythemic vera myelofibrosis~  * Reticulin fibrosis ≥ grade 1~* Evaluable and symptomatic disease worthy of treatment, characterized by ≥ 1 of the following:~  * Anemia, defined as hemoglobin \< 11 g/dL or erythrocyte transfusion dependence~ * Palpable and symptomatic splenomegaly (palpable and symptomatic hepatomegaly is acceptable if previously splenectomized)~ * Severe, disease-related constitutional symptoms, including ≥ 1 of the following:~    * Severe night sweats~   * Fevers~   * Weight loss~   * Bone pain~* Absence of t(9;22) by fluorescent in situ hybridization (FISH) or standard cytogenetics OR prior demonstration of a lack of this translocation~PATIENT CHARACTERISTICS:~* Eastern Co-operative Oncology Group (ECOG) performance status 0-3~* Absolute neutrophil count (ANC) ≥ 1,000/mm³~* Platelet count ≥ 50,000/mm³~* Creatinine ≤ 2.0 mg/dL~* Direct or total bilirubin ≤ 2.0 mg/dL~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times upper limit of normal (ULN) (≤ 5 times ULN if elevation is attributed to hepatic extramedullary hematopoiesis)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Not incarcerated in a municipality, county, state, or federal prison~* No serious medical condition or psychiatric illness that would preclude signing the informed consent~* No condition that, in the opinion of the treating physician, places the patient at unacceptable risk for study participation or confounds the ability to interpret study data~* Able to adhere to the study visit schedule and other study requirements~PRIOR CONCURRENT THERAPY:~* No other concurrent chemotherapy (e.g., hydroxyurea, thalidomide, interferon alpha, anagrelide, or other myelosuppressive agent) or experimental therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).